Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tahoe Therapeutics

Request full access

AI-powered in vivo drug discovery platform.

South San Francisco, United StatesFounded 2022Biotech & Life Sciences

About Tahoe Therapeutics

Tahoe Therapeutics is a biotechnology company engineering AI-powered models of human cells to facilitate the design of improved drugs for a wider range of patients. The company was established in 2022 as Vevo Therapeutics and rebranded to Tahoe Therapeutics in April 2025. It was co-founded by CEO Nima Alidoust, CSO Johnny Yu, Hani Goodarzi, and Kevan Shokat. The founding team combines deep expertise in single-cell genomics, machine learning, and drug discovery. The company's scientific basis originates from Yu's doctoral research at the University of California San Francisco (UCSF), where he, Goodarzi, and Shokat developed the core technology. Tahoe addresses a primary challenge in drug discovery: the high failure rate of drugs developed using traditional in vitro models, which often do not accurately represent complex diseases in humans. The company's core technology is the Mosaic™ platform, which enables in vivo data generation at a massive scale and with single-cell precision. This platform allows for the pooling of cells from hundreds of diverse patient models into a single experiment, such as a mosaic tumor implanted in a mouse, to measure how different cells react to thousands of compounds. This method captures the heterogeneity of disease and drug response across different patients and organs, a significant advancement over standard preclinical research. Using Mosaic, Tahoe is building the world's largest in vivo atlas of how drugs interact with patient cells. A key achievement is the creation of Tahoe-100M, a gigascale single-cell dataset with 100 million data points mapping 60,000 drug-cell interactions. This dataset, 50 times larger than previously available public perturbation data, is used to train the company's AI models to uncover novel drug targets and candidates, particularly for hard-to-treat cancers. The company's initial focus is on oncology, specifically targets within the RAS network. Tahoe's business model involves leveraging its platform for internal drug development and strategic partnerships. The company is advancing its own therapeutic programs towards clinical trials and plans to collaborate with a major pharmaceutical or AI company to share its next, larger dataset to accelerate the development of new medicines or AI models. In January 2026, Tahoe formed a joint venture with Alloy Therapeutics to develop antibody-drug conjugates for difficult cancers. Headquartered in South San Francisco, California, Tahoe has secured $42 million in total funding, with a valuation of $120 million as of August 2025. Its investors include Amplify Partners, General Catalyst, Wing Venture Capital, and Databricks Ventures.

Source: Dealroom company data

At a glance

Status
Operational
Employees
35
Open positions
1
Dealroom signal
91.3/100
Industry
Health
Sub-industry
BioTechnology, Health Platform
Sector
Biotechnology, Oncology, Drug Development, Core AI, AI Drug Discovery, CompBio
Technology
Artificial Intelligence, Big Data, Deep Tech
Business model
SaaS
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Aug 2025 $30M $120M Overlap Holdings · Conviction · Databricks Ventures · General Catalyst ↗
SEED✓Equity / VC Dec 2022 $12M $48M Camford Capital · AIX Ventures · Wing Venture Capital · Mubadala Capital ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Tahoe Therapeutics website traffic

Latest recorded traffic for Tahoe Therapeutics is 5.7K monthly website visits, down 18.6% over the last three months. Tahoe Therapeutics's team grew 12.9% over the past year.

Latest monthly visits5.7K 3-month web change-18.6% 1-year team growth+12.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Tahoe Therapeutics in the South San Francisco ecosystem

Live from Dealroom

The Tahoe Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed5 investors entered at this stage

Series A5 investors entered at this stage

  • Amplify Partners
  • Overlap Holdings
  • Conviction
  • Databricks Ventures
  • Civilization Ventures

Other known investors2 additional known investors

  • Ayman Alabdallah
  • Shaun Johnson
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States75.9%
🇨🇦 Canada24.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tahoe Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tahoe Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.